The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Stabilization of p53 by CP-31398 Inhibits Ubiquitination without Altering Phosphorylation at Serine 15 or 20 or MDM2 Binding
Abstract
CP-31398, a styrylquinazoline, emerged from a high throughput screen for therapeutic agents that restore a wild-type-associated epitope (monoclonal antibody 1620) on the DNA-binding domain of the p53 protein. We found that CP-31398 can not only restore p53 function in mutant p53-expressing cells but also significantly increase the protein level and promote the activity of wild-type p53 in multiple human cell lines, including ATM-null cells. Cells treated with CP-31398 undergo either cell cycle arrest or apoptosis. Further investigation showed that CP-31398 blocks the ubiquitination and degradation of p53 but not in human papillomavirus E6-expressing cells. Of note, CP-31398 does not block the physical association between p53 and MDM2 in vivo. Moreover, unlike the DNA-damaging agent adriamycin, which induces strong phosphorylation of p53 on serines 15 and 20, CP-31398 exposure leads to no measurable phosphorylation on these sites. We found that CP-31398 could also stabilize exogenous p53 in p53 mutant, wild-type, and p53-null human cells, even in MDM2-null p53(-/-) mouse embryonic fibroblasts. Our results suggest a model wherein CP-31398-mediated stabilization of p53 may result from reduced ubiquitination, leading to high levels of transcriptionally active p53. Further understanding of this mechanism may lead to novel strategies for p53 stabilization and tumor suppression in cancers, even those with absent ARF or high MDM2 expression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“CP-31398 inhibited ubiquitination and degradation of p53457 and activated BAX independently of p53 to promote apoptosis of tumor cells.455”
From Targeting p53 pathways: mechanisms, structures, and advances in therapy (2023) · cites this paper as [457]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506
Regulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312 · cited 3×
“Under physiological conditions, p53 is under strict control with a very short half-life, in part due to the MDM2p53 autoregulatory feedback loop (19, 25, 49).”
BackgroundDNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2
Shieh, S.-Y., Ikeda, M., Taya, Y., & Prives, C. (1997) · Cell · doi:10.1016/s0092-8674(00)80416-x · Cited by 2,100
mdm2 expression is induced by wild type p53 activity.
Barak, Y., Juven, T., Haffner, R., & Oren, M. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb05678.x · Cited by 1,290
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
Bykov, V. J. N., Issaeva, N., Shilov, A., Hultcrantz, M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K. G., & Selivanova, G. (2002) · Nature Medicine · doi:10.1038/nm0302-282 · Cited by 1,067
Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2
Kamijo, T., Weber, J. D., Zambetti, G., Zindy, F., Roussel, M. F., & Sherr, C. J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.14.8292 · Cited by 899
Association of p19ARF with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53
Honda, R., & Yasuda, H. (1999) · The EMBO Journal · doi:10.1093/emboj/18.1.22 · Cited by 724
MDM2 suppresses p73 function without promoting p73 degradation
Zeng, X., Chen, L., Jost, C. A., Maya, R., Keller, D., Wang, X., Kaelin, W. G., Oren, M., Chen, J., & Lu, H. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.5.3257 · Cited by 334
Research works printed but not linked: 42
- 10.1006/excr.1998.4193 · DOI
- 10.1128/MCB.20.9.3224-3233.2000 · DOI · Paper page
- Banerjee D., 2001, Anticancer Res., 21, 3941
- 10.1038/sj.onc.1204204 · DOI
- 10.1038/sj.onc.1201374 · doi:10.1038/sj.onc.1201374
- 10.1038/sj.onc.1202480 · DOI · Paper page
- 10.1073/pnas.96.24.13777 · DOI · Paper page
- 10.1042/bj3590459 · doi:10.1042/bj3590459
- 10.1016/S0955-0674(00)00201-5 · DOI · Paper page
- 10.1006/scbi.1998.0097 · DOI · Paper page
- 10.1074/jbc.275.12.8945 · DOI · Paper page
- 10.1126/science.286.5449.2507 · DOI · Paper page
- 10.1073/pnas.241629998 · DOI · Paper page
- 10.1038/35023507 · DOI · Paper page
- 10.1128/MCB.20.4.1243-1253.2000 · DOI
- 10.1128/MCB.21.24.8533-8546.2001 · DOI
- 10.1073/pnas.95.5.2509 · DOI · Paper page
- 10.1073/pnas.97.15.8501 · DOI · Paper page
- Hollstein M., 1994, Nucleic Acids Res., 22, 3551
- 10.1128/MCB.17.1.460 · DOI · Paper page
- 10.1038/sj.onc.1204883 · DOI
- 10.1038/nature737 · DOI · Paper page
- 10.1038/sj.onc.1204615 · DOI
- 10.1128/MCB.21.24.8521-8532.2001 · DOI · Paper page
- 10.1006/excr.2002.5526 · DOI
- Maki C. G., 1996, Cancer Res., 56, 2649
- 10.1016/S1097-2765(01)00284-2 · DOI · Paper page
- Prabhu N. S., 1998, Int. J. Oncol., 13, 5
- 10.1038/sj.onc.1205362 · DOI · Paper page
- 10.1016/S0027-5107(00)00089-0 · DOI
- 10.1128/MCB.19.5.3395 · DOI · Paper page
- 10.1074/jbc.M202296200 · DOI
- 10.4161/cbt.1.1.42 · DOI
- 10.1111/j.1749-6632.2000.tb06705.x · DOI · Paper page
- 10.4161/cbt.1.1.41 · DOI
- 10.1093/emboj/18.7.1805 · DOI · Paper page
- 10.1038/35091170 · DOI
- 10.1016/S0092-8674(00)00171-9 · DOI · Paper page
- 10.1038/ng1097-141 · DOI · Paper page
- 10.1006/excr.2001.5314 · DOI
- 10.1074/jbc.M004894200 · DOI
- 10.1038/sj.onc.1203980 · DOI
Cited by
Haupt, S., Berger, M., Goldberg, Z., & Haupt, Y. (2003) · Journal of Cell Science · doi:10.1242/jcs.00739 · Cited by 1,136
Targeting p53 pathways: mechanisms, structures, and advances in therapy
Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016
Targeting mutant p53 for efficient cancer therapy
Bykov, V. J. N., Eriksson, S. E., Bianchi, J., & Wiman, K. G. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.109 · Cited by 889
Understanding Apoptosis and Apoptotic Pathways Targeted Cancer Therapeutics
Jan, R., & Chaudhry, G.-E.-S. (2019) · Advanced Pharmaceutical Bulletin · doi:10.15171/apb.2019.024 · Cited by 899
TRAIL and apoptosis induction by TNF-family death receptors
Wang, S., & El-Deiry, W. S. (2003) · Oncogene · doi:10.1038/sj.onc.1207232 · Cited by 871
Self-citation
Metadata
- Authors
- Wang, W., Takimoto, R., Rastinejad, F., & El-Deiry, W. S.
- Affiliations
- Laboratory of Molecular Oncology and Cell Cycle Regulation, Howard Hughes Medical Institute, Departments of Medicine, Genetics, Pharmacology, and Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104
- Cancer Drug Discovery, Pfizer Global Research and Development, Groton, Connecticut 06340
- Venue
- Molecular and Cellular Biology
- Publisher
- Informa UK Limited
- Published
- 2003-03-01
- Volume
- 23
- Issue
- 6
- Pages
- 2171-2181
- ISSN
- 1098-5549
- Cited by
- 126
- References
- 8
- Language
- en
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.